All News

gout.podagra_0.jpg

2010 Colchicine Price Hikes Adversely Affected Gout Care

Jack Cush, MD

Researchers from Harvard have reported their analysis showing that the large increase in colchicine cost in 2010 was associated with an immediate decrease in colchicine prescription use, with a 10 year increase in emergency department and rheumatology gout visits suggesting poorer gout control.

Read Article
CV,risk,MI,heart,cardiac

Romosuzumab and Low Sclerostin Levels Underlie CV Risk

EurekAlert!

New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS.

Read Article
brain headache neuro

Treatment and Management of Neuropsychiatric Lupus

Eric Dein, MD

On the first day of ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder. 

Read Article
pneumocystis,PJP

PJP Prophylaxis Needed with Steroids and Rituximab

Jack Cush, MD

Pneumocystis jirovecii pneumonia (PJP) can be a life-threatening infection in immunocompromised patients. The 2023 EULAR Vasculitis guidelines recommends primary prophylaxis with antibiotics, especially in rheumatic disease patients receiving rituximab (RTX).

Read Article
RheumNow Podcast square

National Population Insights (4.28.2023)

Jack Cush, MD

Dr. Jack Cush reviews the news and journal reports and addresses 3 viewer case questions.

Read Article
diabetes.jpg

Denosumab Reduces Type II Diabetes Risk

Jack Cush, MD

The British Medical Journal has publish a matched cohort analysis demonstrating that adults receiving denosumab had a lower risk of incident type 2 diabetes (NIDDM) compared with those taking oral bisphosphonates for osteoporosis.

Read Article
gout_s.jpg

A Rising Gout Risk in Asians

Jack Cush, MD

Two independent data sets suggests the prevalence of gout among Asians has grown such that this sub-population has numerically surpassed all other racial and ethnic groups by 2018.

Read Article
RheumNow Podcast square

Want to Go Far, Go Together (4.21.2023)

Jack Cush, MD

This week on the podcast Dr. Jack Cush reviews the news, regulatory announcements and novel journal reports including a profile on pseudogout, the safety of immune checkpoint inhibitors in RA patients and the diagnostic importance of neutrophils.

Read Article
psA.fil_.toes_.jpg

Sex-Specific Differences in Psoriatic Arthritis

Jack Cush, MD

A systematic review of published literature on psoriatic arthritis (PsA), clinical features, disease activity, and patient-reported outcomes (PROs) shows generally higher levels of disease activity in women, compared to men with PsA.

Read Article
Have a Rheumatology question or case for Jack Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/0mC7PxF0DU https://t.co/klbnwjcPbM

Links:

Dr. John Cush RheumNow ( View Tweet)
In 2020 Filgotinib (Jyseleca) did not seek FDA approval over FDA concerns & pending RCTs on safety & spermatogenesis. Now the results (MANTA & MANTA-RAy) are published showing FIL has no effect on semen & sex hormones. But still no filgotinib in USA https://t.co/4IHoOpylXm https://t.co/VPqW5Ktcc4

Links:

Dr. John Cush RheumNow ( View Tweet)
Romosuzumab and Low Sclerostin Levels Underlie CV Risk New research highlights potential safety concerns around women taking romosozumab, a new anti-osteoporosis drug available on the NHS. https://t.co/tRGOXrm0Fk https://t.co/ebiRpCC81p

Links:

Dr. John Cush RheumNow ( View Tweet)
#RNL2023 @RheumNow Dr. Stanley Cohen: possible adverse effects of JAKi -Herpes zoster, other infections -Malignancy -Occasional cytopenias -LFTs (with DMARDs) -Incr Cr or CPK -Acne -Incr lipids -GI perf -VTE Which do you counsel with your patients? https://t.co/zncCw3jlK7 https://t.co/AHhDyxaumM

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Stanley Cohen on JAKinibs: Very concise and informative timeline on the multiple JAKinibs approved for multiple conditions @RheumNow #RNL2023 https://t.co/ulLh2HikUt https://t.co/0kR8CNZvsV

Links:

Dr. John Cush RheumNow ( View Tweet)
UK's MHRA has followed EMA final ruling regarding new Safety recs & JAK inhibitors: - RE: tofacitinib, abrocitinib, baricitinib, upadacitinib & filgotinib use in chr inflammatory Dz. - avoid JAKi if no suitable alternative: age >=65, smokers, CV/CA Hx https://t.co/Y1vZPHPEPN https://t.co/odovKWebFV

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us this Tuesday for our the start of our May Tuesday Night Rheumatology focusing on Rheumatoid Arthritis: Revolutionary Advances in Therapy https://t.co/TbNYaGJ3sk https://t.co/DiJwjvUX1d

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Alexis Ogdie discusses sex differences in patients with psoriatic arthritis. Learn more. https://t.co/JTSHAKBfhN https://t.co/f0rfDQAY6T

Links:

Dr. John Cush RheumNow ( View Tweet)
Join us 4/25 as we conclude our Women in Rheumatology campaign by focusing on what's next. Our panelists will recap the challenges addressed this month and discuss a strategy to suppot women in rheumatology. https://t.co/DP4S2hf5Tz @uptoTate @KDAO2011 @gwenesta_melton https://t.co/rcglaZxqoF

Links:

Dr. John Cush RheumNow ( View Tweet)
TNR: Private Practice & Academia In this session, our panelists addressed the big questions of: "How do I choose between private practice and academia?" and "How do I advance in my career?". https://t.co/yMJ5mCtSXX @KDAO2011 https://t.co/eeFYkLYsAh

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Philip Mease speaks about the effect of sex and gender on rheumatology disease activity and treatment response. Learn more. https://t.co/vKZfFLFmgs https://t.co/kRA0w9hRX7

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×